Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFM11 in Relapsed/Refractory Adult B-precursor ALL
NCT02848911Phase 1Terminated
- Sponsor
- Affimed
- Start
- Oct 2016
- Primary completion
- Sep 2018
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of AFM11 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Affimed. Primary endpoint: Number of participants with serious and non-serious adverse events. Started Oct 2016; status: terminated.
02
Drugs
AFM11
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02848911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02848911.